Introduction {#Sec1}
============

The extracellular signal-regulated kinase/mitogen-activated protein kinase (ERK/MAPK) pathway is a signaling cascade involved in diverse cellular functions such as growth, proliferation, and differentiation \[[@CR1]\]. Recently, via pharmacological inhibition of ERKs' upstream activators MEK1 and MEK2, a role for ERK1 and ERK2 was also proposed in mature neurons of the rat lateral amygdala (LA) in fear learning \[[@CR2]\]. Several brain disorders, like anxiety disorders, are characterized by disturbed fear learning processing \[[@CR3]\]. Therefore, the analysis of the molecular pathways responsible for normal and pathological development of fear learning and the search for clinically effective therapeutic tools are highly relevant. Via the analysis of knockout mice for Erk1 and Erk2, it was suggested that the lack of ERK1 does not impair emotional learning \[[@CR4]\], while the partial inactivation of ERK2 can affect long-term fear learning \[[@CR5]\]. But the simultaneous and ubiquitous expression of *Erk1* and *Erk2* genes in many regions of the adult murine CNS \[[@CR6]\] suggests that the analysis of single knockout animals for these genes is not sufficient to clarify their specific role, due to their potential redundancy which could mislead data interpretation. Thus, classical pharmacology as well as knockout technologies encounter limitations due to: (i) the lack of pharmacological inhibitors targeting specifically the ERKs; (ii) the laborious methods necessary for the generation and analysis of single or multiple knockout mice; (iii) the limited number of region-specific promoter regions to allow restricted loss-of-function studies. The discovery of RNA interference (RNAi) can help in mitigating such limitations, allowing the silencing of the expression of single or multiple genes in an efficient and quick manner \[[@CR7]\]. In addition, the possibility of using short interfering RNA (siRNA) \[[@CR8]\] or short hairpin RNA (shRNA) \[[@CR9]\] to trigger RNAi in cells, in combination with viral vectors to perform somatic genetic manipulation, facilitates the specific loss-of-function analysis in selected brain areas \[[@CR10]\]. In particular, adeno-associated virus (AAV) reagents have been successfully used to perform gene transfer in the brain via stereotaxic injection \[[@CR11], [@CR12]\], as they show several advantages: (i) adaptable diffusion of the vector at the injection site by using different virus serotypes \[[@CR13]\]; (ii) predominant infection of neurons rather than glia cells \[[@CR14]\]; (iii) very low integration efficiency (0.1--0.5%) in the genome of infected cells \[[@CR15]\].

In this study, we show the selection and in vitro validation of shRNAs to target and downregulate both *Erk1/2* simultaneously, or specifically *Erk2*, leaving *Erk1* unaffected. The further in vivo analysis of AAV-mediated downregulation of *Erk2* confirmed our shRNA as a valid tool for the local inhibition of this gene in neurons of the adult mouse brain. This opens the avenue for further studies to analyze the region-specific contribution of ERK2 to the development of anxiety and other psychiatric disorders.

Materials and Methods {#Sec2}
=====================

Selection and Validation of shRNA In Vitro {#Sec3}
------------------------------------------

A Bluescript plasmid containing the human U6 promoter from pSHAG \[[@CR16]\] was opened with BseRI/BamHI and ligated with an *Erk2*-specific oligonucleotide pair (Erksh4) or an *Erk1/2*-specific oligonucleotide pair (Erksh6) (for sequences see Fig. [1](#Fig1){ref-type="fig"}b). The *LacZ*-specific shRNA vector has been described previously \[[@CR17]\]. All plasmids were grown in DH5α, isolated with QIAgen plasmid Maxiprep columns and the integrity of the promoter and shRNA regions was confirmed by DNA sequencing. Mouse F1 ES cells (IDG3.2) were used for transient transfections. ES cells were grown in DMEM medium (Gibco) containing 12.5% FCS, 20 mM HEPES pH 7.2, 0.1 mM MEM non-essential amino acids (Gibco, Cat. No.: 11140--035), 0.1 mM 2-mercaptoethanol, and 90 μl LIF (10^7^ U/ml, Chemicon) on gelatine coated culture dishes. About 2 × 10^6^ cells were electroporated with each shRNA plasmid and cultivated for 48 h. Cells were then homogenized in lysis buffer (2% SDS, 50 mM Tris pH 6.8, 50 mM DTT, 10% Glycerol, Protease inhibitor cocktail (Roche, Cat. No.: 11697498001)), and protein concentrations were determined with the BCA test (Pierce) in comparison to BSA as standard; 20 μg of each sample were heat denatured, separated on a SDS-PAGE gel, and blotted on PVDF membranes (Pall). Membranes were blocked in 3% BSA in phosphate-buffered saline with 0.1% Tween 20 (PBS-T) for 24 h at 4°C, incubated with rabbit anti-ERK1/2 (1:1000, Cell Signaling Technology) 1 h at RT, washed in PBS-T, and incubated with HRP-goat anti-rabbit (1:1000, Jackson ImmunoResearch) 1 h at RT. After washing, signals were visualized with ECL reagents (Amersham Biosciences) and films were scanned and processed with Adobe Photoshop. For shRNAs that showed performance in Western blot experiments real-time qRT-PCR analysis was performed in addition. Briefly, total RNA was extracted from cells with the Invisorb RNA Kit (Invitek), cDNA synthesis was performed with ABI HighCapacity cDNA reagents and qRT-PCR (Quantace SybrGreen qPCR mix) was run with an ABI 7900HT machine.Fig. 1Schematic drawings of shRNA constructs for in vitro/in vivo studies. **a** For in vitro studies, the short hairpin RNAs were cloned in pBluescript vector under the control of the U6 promoter (U6). **b** Sequences of the hairpins tested for their downregulation efficiency via Western blot, after electroporation of the shRNA vector constructs into ES cells. Sequences of the hairpin-loops are underlined. **c** Schematic representation of the recombinant AAV vector genome AAV-CMV-Venus-U6shRNA. The two expression cassettes for the reporter Venus and the shRNA are separated by a 1.0 kb stuffer element and the genome is flanked by two 141 bp inverted terminal repeats. *ITR* inverted terminal repeats; *CMV* cytomegalovirus promoter; intron: β-globin intron; Venus: yellow fluorescent protein Venus; pA: human growth hormone polyA signal; stuffer: stuffer element; U6: U6 promoter; LacZsh: control hairpin; Erksh4: hairpin against Erk2

Construction of rAAV Vector Plasmid {#Sec4}
-----------------------------------

Two expression cassettes---one for the yellow fluorescent protein Venus and one either for the shRNA targeting *Erk2* or *LacZ*---were cloned into the pAAV-MCS plasmid (Stratagene) to obtain the expression plasmid CMV-Venus-U6shRNA. Venus is a yellow variant of the green fluorescent protein GFP, detectable with anti-GFP antibodies \[[@CR18]\]. The expression of the reporter gene and the shRNA are driven by the RNA polymerase II-driven CMV and the RNA polymerase III-driven U6 promoter, respectively. The expression cassettes are separated by a non-functional stuffer sequence cloned from the 3′ end of the β-galactosidase gene to obtain an optimal AAV genome size of 4.7 kb.

Production of rAAV Vector {#Sec5}
-------------------------

For vector preparation, ten 100-mm petri dishes of HEK293-derived AAV-293 cells (Stratagene) were transfected by the calcium phosphate technique with 300 μg of plasmid DNA (expression plasmid, pHelper and pAAV-RC, 100 μg each) according to the AAV Helper-Free System manual (Stratagene). After 4 days of incubation, cells were harvested and lysed two times by freeze and thaw technique. Afterward the viral particles were separated from the cell debris by centrifugation.

Purification of rAAV Vector {#Sec6}
---------------------------

Virus suspensions were purified by a single-step column purification \[[@CR19]\]; modified protocol) using a heparin-agarose matrix. Viral particles were washed twice with PBS, pH 7.4 and eluted in PBS, pH 7.4 plus 0.5 M NaCl. This eluate was desalted and concentrated with an Amicon Ultra centrifugal filter device (Millipore, 100 K NMWL).

Characterization of Viral Vectors {#Sec7}
---------------------------------

The purity of viral preparations was assessed by electrophoresis on SDS-PAGE gels. Total protein was stained by the Coomassie method. Determination of the genomic titer was achieved by dot blot analysis: a viral sample was degraded with protease K and loaded on a nitrocellulose membrane. As control, a dilution series of viral cloning plasmids was loaded. For autoradiography, a probe matching the Venus-coding region of the viral genome was used. The in vitro transduction efficiency of viral vectors was determined by incubation of HT1080 cells with a diluted virus preparation. Infected cells expressing the Venus reporter gene were identified by fluorescence microscopy.

Viral Injections and Tissue Preparation for Immunohistochemistry {#Sec8}
----------------------------------------------------------------

C57BL/6J adult male mice (Charles River) were anesthetized and stereotaxically injected bilaterally with 1 μl/side of AAV preparation into the amygdala. Injections were performed at 0.25 μl/min rate and injectors were left in place for one additional min to allow diffusion of the virus from the tip. Injection coordinates \[[@CR20]\] were: −1.7 mm anteroposterior, ±3.4 mm mediolateral, and −4.0 mm dorsoventral. After 1 week, mice were killed and perfused with 4% paraformaldehyde; brains were removed, post-fixed overnight, and cryoprotected in 25% sucrose in PBS. Coronal cryosections (30 μm) were cut through the area of the amygdala and kept in cryoprotective solution at −20°C until processed. Experiments involving animals were carried out in accordance with national and institutional guidelines.

Immunofluorescent-Immunohistochemistry (IF-IHC) and in situ Hybridization (ISH) {#Sec9}
-------------------------------------------------------------------------------

For the IF-IHC co-localization studies, sections were washed in PBS and incubated with chicken anti-green fluorescent protein antibody (anti-GFP, Aves Lab, 1:500), together with either the specific neuronal marker anti-NeuN (mouse, 1:200, Chemicon) or the specific glial marker anti-S100β (mouse, 1:1000, Sigma) in 10% normal goat serum/0.5% Triton X-100 in PBS, overnight at 4°C. On the second day, sections were washed and incubated overnight at 4°C with the secondary fluorophore-conjugated antibodies (FITC-anti-chicken, Aves Lab, and TRITC-anti-mouse IgG1, Southern Biotech, both 1:200) and with the nuclear marker DAPI (Sigma). On the third day, sections were washed and mounted onto poly-[l]{.smallcaps}-lysine-coated slides for confocal microscopy analysis. For the IF-IHC/ISH co-localization studies, the plasmid containing the cDNA for the *Erk2* probe was linearized with the appropriate enzyme, purified (PCR purification Kit, QIAgen), and the DIG-labeled probe was prepared by in vitro transcription with DIG RNA Labeling Kit (SP6/T7) (Roche), following manufacturer's instructions. After DNase I (Roche) treatment, the probes were purified by the RNeasy Clean up protocol (QIAgen) and measured in a dot-blot assay, comparing serial dilutions of probe to DIG-labeled control RNA standards. For the ISH procedures, briefly: free-floating sections were rinsed in PBS and endogenous peroxidase quenched with 30 min incubation in 0.3% H~2~O~2~ in PBS. Sections were then rinsed in PBS and incubated 15 min in 5× SSC (0.75 M NaCl, 0.75 M Na-citrate). Afterward, they were incubated 1 h at 58°C in pre-hybridization solution (5× SSC, 50% formamide, pH 7.5 with HCl, 50 μg/ml salmon sperm) and overnight at 58°C in hybridization solution (pre-hybridization solution with 500 ng/ml of DIG-labeled probe). On the second day, sections were washed 1 h at 65°C in 2× SSC, then rinsed in PBS, and blocked 30 min in PBS-BB (PBS with 1% BSA, 0.2% powdered skim milk, 0.3% Triton X-100). Afterward, they were incubated 1 h in HRP-conjugated anti-DIG antibody (Roche), washed in PBS and in PBST (0.5% Triton X-100 in PBS). For amplification of the signal, sections were incubated 20 min in Tyramid Signal Amplification solution (TSA, Perkin Elmer) (dilution 1:50 in its own diluent solution). They were then rinsed in Maleic acid buffer (MB, 0.1 M Maleic acid, 0.15 NaCl, pH 7.5 with NaOH) and incubated 30 min in Neutravidin solution (Pierce) (dilution 1:750 in Maleic acid blocking buffer (1% blocking reagent, Roche, in MB)). After a wash in MB, sections were rinsed in Detection buffer (0.1 M Tris--HCl, pH 9.5; 0.05 M MgCl~2~; 0.1 M NaCl) and developed in Developing solution (0.5 mg/ml NBT, 0.375 mg/ml BCIP (Roche) in Detection buffer). When a clear signal was visible, sections were washed in PBS and incubated overnight with chicken anti-GFP antibody (as above, 1:500) in 10% goat serum/0.5% TX-100 in PBS. After washing in PBS, sections were incubated overnight with the secondary fluorescent-conjugated antibody (FITC-anti-chicken, as above, 1:200) in 10% goat serum/0.5% TX-100 in PBS. After washing, sections were mounted on poly-[l]{.smallcaps}-lysine-coated slides, covered with anti-fading AquaPolyMount (Polysciences) and coverslips, and dried before confocal microscopy analysis.

Microscopy Data Analysis {#Sec10}
------------------------

The analysis was performed using a confocal microscope (Olympus, equipped with the FluoView1000 Software), scoring through amygdala's sections, from anterior to posterior levels, on both left and right sides, in at least two brains for each injected viral vector.

Results {#Sec11}
=======

Development and in vitro Test of *Erk*-Specific shRNA Vectors {#Sec12}
-------------------------------------------------------------

Short hairpins targeting *Erk1/2* or *Erk2* alone were cloned into an expression vector under the control of the human U6 promoter (Fig. [1](#Fig1){ref-type="fig"}a, b). These vectors were electroporated into embryonic stem (ES) cells to test their gene silencing efficiency in vitro. Two days after transfection cells were lysed and the levels of ERK1 and ERK2 proteins were analyzed by western blotting of protein extracts. As shown in Fig. [2](#Fig2){ref-type="fig"}, both Erksh4 and Erksh6 did reduce ERK2 levels, but with different efficiencies. Notably, Erksh6 also seemed to reduce partially ERK1 activity (Fig. [2](#Fig2){ref-type="fig"}a, b). Therefore, we further analyzed the downregulation efficiency of both Erksh4 and Erksh6 via quantitative RT-PCR. As shown in Fig. [2](#Fig2){ref-type="fig"}b, Erksh4 almost completely inactivated *Erk2* (4.6% remaining mRNA level), leaving *Erk1* unaffected. In contrast, the Erksh6 vector also reduced *Erk1* mRNA (57.6% remaining mRNA level). As we were interested in the specific inactivation of *Erk2*, the Erksh4 cassette was further used for in vivo experiments.Fig. 2Western blot and qRT-PCR analysis of downregulation efficiency of shRNA vectors. **a** ShRNA vectors were tested in ES cells, as described in section ["Materials and Methods"](#Sec2){ref-type="sec"}; Western blot analysis revealed that Erksh4 and Erksh6 downregulated specifically ERK2, as compared to control samples ("Ctrl"). **b** Erksh4 and Erksh6 were further analyzed with qRT-PCR; the results confirmed the specific and significant reduction in ERK2 expression for Erksh4, while Erksh6 reduced ERK2, but affected also *Erk1* mRNA level, and was therefore excluded from further experiments. Error bars show minimal and maximal results from triplicate measurements

Performance of Viral shRNA Vectors in vivo {#Sec13}
------------------------------------------

To generate a viral shRNA expression vector the CMV-Venus-U6Erksh4 expression unit was cloned into the backbone of AAV2 (Fig. [1](#Fig1){ref-type="fig"}c). As control, a shRNA targeting the mRNA coding for β-galactosidase (*LacZ*) was used (LacZsh). As shown in Fig. [1](#Fig1){ref-type="fig"}c, a stuffer sequence separated the U6-shRNA cassette from a second cassette expressing the yellow fluorescent protein (YFP) Venus under control of the CMV promoter, to allow the identification of infected cells upon in vivo injections. These viral preparations were stereotaxically injected into the LA of adult mice. The AAV2 vectors showed a clear preferential tropism for neurons (labeled with the specific neuronal marker NeuN \[[@CR21]\]) and not for glia cells (labeled with the specific glial marker S100β \[[@CR22]\]), as shown by immunohistochemistry for either DAPI/NeuN/Venus (Fig. [3](#Fig3){ref-type="fig"}b) or DAPI/S100β/Venus (Fig. [3](#Fig3){ref-type="fig"}c); moreover, the cells infected with the CMV-Venus-U6Erksh4 virus (YFP^+^, Fig. [3](#Fig3){ref-type="fig"}h, white arrow) showed the specific downregulation of *Erk2* mRNA (Fig. [3](#Fig3){ref-type="fig"}i, red arrow), while those transduced with the control CMV-Venus-U6LacZsh virus (YFP^+^, Fig. [3](#Fig3){ref-type="fig"}f, white arrowhead), still showed *Erk2* mRNA signals (Fig. [3](#Fig3){ref-type="fig"}g, red arrowhead). We quantified the proportion of double labeled cells (YFP^+^; *Erk2*^+^) in comparison to the total number of infected cells (YFP^+^) cells for both injected viral vectors in randomly selected section areas from the LA. As shown in Fig. [3](#Fig3){ref-type="fig"}k, the relative number of *Erk2*^+^ cells in the control injected animals (LacZsh) was similar to the total number of only YFP^+^ cells (91.7 ± 8.3%) while this number was strongly reduced in the CMV-Venus-U6Erksh4 injected animals (Erksh4, 2.9 ± 2.2%). A one-way ANOVA analysis of the results confirmed a significant difference between the two groups (*F*~(1)~ = 13.38; \*\* *P* ≤ 0.01). These in vivo results confirmed those obtained in vitro with the qRT-PCR (Fig. [2](#Fig2){ref-type="fig"}c) which showed the high efficiency of this shRNA in silencing Erk2 mRNA.Fig. 3Tropism and downregulation efficiency of Erksh4 in vivo. **a** Schematic drawing of the amygdala at approximately −1.82 mm from bregma (according to (Franklin and Paxinos, 1997)). **b**, **c** Tropism of the virus. Representative photomicrographs of a portion of the LA (blue square in (**a**)) which show the site of injection, immunostained for YFP (green) and NeuN (red) (**b**) and for YFP (green) and S100β (red) (**c**); ounterstaining with DAPI (blue) shows the single-cell nuclei. (**d′**, **d″**, **d′′′**) Higher magnification of labeled cells (white square (D) in (**b**)) to show the single signals for NeuN (**d′**) and venus (**d″**) and the yellow color of their "merge" (D′′′) which highlights their co-localization; (**e′**, **e″**, **e′′′**) higher magnification of labeled cells (white square (E) in (**c**)) to show the single signals for S100 β (**e′**) and venus (**e″**): in contrast with (**d′′′**), their "merge" (**e′′′**) shows only a faint co-localization of the two signals (**f**, **g**, **h**, **i**). Downregulation of Erk2 mRNA. Higher magnification of labeled cells showing the specificity of downregulation in YFP^+^ cells infected with the Erksh4 virus (**h**, **i**) in comparison to YFP^+^ cells infected with the control virus (**f**, **g**): in (**f**, **g**) a clear ISH signal for *Erk2* mRNA is visible in control infected cells (arrow heads), as high as in YFP^−^ neighboring cells (asterisks); while in (**h**, **i**) the ISH signal is absent from YFP^+^ cells (arrows), although still present in neighboring YFP^−^ cells (squares). **k** Double positive cells for YFP and *Erk2* mRNA were counted in randomly selected sections from the amygdala of the four injected animals (*n* = 2 for each virus, bilaterally injected). The number of YFP^+^, Erk2^+^ cells was compared to the number of only YFP^+^ cells. As shown in the figure, in the control injected animals (LacZsh), the relative number of Erk2^+^ cells was not significantly different from the only YFP^+^, while in the Erksh4 injected brains, this number was significantly reduced (ANOVA; \*\* *P* ≤ 0.01), indicating an efficient downregulation of *Erk2* also in vivo. Scale bars = 125 μm in (**b**, **c**); 60 μm in D--**d'''** and E--**e'''**; 10 μm in (**f**, **g**, **h**, **i**)

Discussion {#Sec14}
==========

In this study we identified shRNAs that efficiently knockdown the expression of either ERK1/2 simultaneously or only ERK2 in vitro (Fig. [2](#Fig2){ref-type="fig"}a, b). By using AAV as delivering agent we also tested the *Erk2*-specific shRNA in vivo and showed a concomitance between the downregulation efficiency in vivo with that obtained in vitro (Fig. [3](#Fig3){ref-type="fig"}). Therefore, our shRNAs can be used as tool for the further in vivo analysis of MAP kinase signaling in the etiopathogenesis of neuropsychiatric diseases. In particular, we found a shRNA, Erksh4, highly efficient for the silencing of *Erk2* expression both in vitro and in vivo, that will prove useful to further analyze the role of this gene in specific regions of the adult brain (Figs. [2](#Fig2){ref-type="fig"} and [3](#Fig3){ref-type="fig"}). Furthermore, we found a shRNA that targets and downregulates both *Erk1* and *Erk2* at the same time, but with different relative efficiency (Erksh6, Fig. [2](#Fig2){ref-type="fig"}a, b); this allows the functional analysis of both genes that are coexpressed in most regions of the adult brain and may exhibit functional redundancy \[[@CR6]\]. With this shRNA we can compensate for the lack of pharmacological agents that inhibit ERK kinase activity and the inconvenience to inactivate both *Erk* genes by gene knockout technology. The differential relative downregulation efficiency makes it a useful tool for unmasking dose-dependent effects eventually related to only partial inactivation of the two genes' functions. With this shRNA it is possible to overcome the limitation of knockout alleles that allow only for 50% or 100% gene inactivation in the heterozygote or homozygote knockout configuration, respectively. In this study we show that AAV-mediated RNAi offers several advantages: (i) it can target molecules which are not amenable for pharmacological compounds; (ii) it targets preferentially neurons (Fig. [3](#Fig3){ref-type="fig"}b, d′′′), (iii) it allows the in vivo dissection of gene function in a restricted regional and temporal manner. These properties make it an excellent tool to unravel the specific neuronal role of *Erk2* in complex behaviors. Nevertheless, to establish the utility of this system for behavioral analysis, additional experiments would be needed. As compared to other viral vectors that do not show neuronal tropism, e.g. lentivirus \[[@CR23]\], the AAV approach offers specific cell-type selectivity. Since also glia cells can participate in the regulation of synaptic plasticity \[[@CR24]\] it is important to validate the tropism of a viral agent that triggers RNAi. Our results of the AAV-CMV-Venus-U6shRNA injections showed a clear concomitance between gene silencing in vitro and in vivo (compare Fig. [2](#Fig2){ref-type="fig"} with Fig. [3](#Fig3){ref-type="fig"}). It is likely that the same concomitance applies to the other shRNA Erksh6, overcoming limitations of other methodologies for gradual and simultaneous gene inhibition. To our knowledge, *Erk2* has been efficiently downregulated only in vitro via lentivirus-mediated RNAi \[[@CR25]\]. Moreover, as recently shown by \[[@CR26]\], there is an evident limitation not only in the availability of pharmacological compounds which target specifically single molecules like the ERKs, but also in the development of such inhibitors to analyze the function(s) of Ser/Thr kinases as ERKs. In this context, our study is relevant in demonstrating that the *Erk2*-specific AAV vector AAV-CMV-Venus-U6Erksh4 provides a useful reagent for the silencing of *Erk2* in vivo, enabling to establish an alternative tool to study anxiety and other neuropsychiatric disorders.
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